Search clinical trials for: eligible for CAR T-cells therapy

Total 407191 results

University Hospital, Toulouse
Janssen, LP; Ligue contre le cancer, France

Not yet recruiting

Real-life Management of Patients Eligible for CAR-T Cell Therapy (CARAVAGE)

Hemopathy

France
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Fred Hutchinson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma

United States
Zhao Weili

Not yet recruiting

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Neogap Therapeutics AB
Karolinska University Hospital; CTC Clinical Trial Consultants AB; Region Västmanland and other collaborators

Recruiting

A First-In-Human Trial of pTTL in Advanced Colorectal Cancer

Colorectal Cancer

Sweden
University of Leipzig
AbbVie; University Hospital Leipzig, Hematology Diagnostics Laboratory; University...

Recruiting

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

Acute Myeloid Leukemia (AML)

Germany
David Bond, MD

Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
IGLESIAS Juan Fernando
Clinical Trials Unit University of Bern

Not yet recruiting

STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (STARS DAPT)

ST Elevation Myocardial Infarction

Switzerland
Immunophotonics, Inc.

Recruiting

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1)

Soft Tissue Sarcoma | Nonsmall Cell Lung Cancer | Metastatic Solid Tumor | Colon Cancer

France, United Kingdom, United States, Germany, Switzerland
Christian Hinrichs

Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical Cancer | HPV-Related Malignancy | Metastatic Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditions

United States
National Institute of Allergy and Infectious Diseases...
NeoImmune Tech

Not yet recruiting

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

Idiopathic CD4 Lymphopenia

United States
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
Children's Oncology Group

Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States, Australia, Canada
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
National Cancer Institute (NCI)

Recruiting

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Kita-kyushu Lung Cancer Antigen 1, Human

United States
Eureka Therapeutics Inc.

Recruiting

T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3)

Hepatocellular Carcinoma | Liver Neoplasm | Metastatic Liver Cancer | Liver Cancer, Adult

United States
John Reneau

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/Lymphoma

United States
Eureka Therapeutics Inc.

Recruiting

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2)

Liver Neoplasms | Hepatocellular Carcinoma (HCC) | Liver Cancer | Hepatoblastoma | Metastatic Liver Cancer | HEMNOS

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Prof. Aviram Nissan

Not yet recruiting

Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial

Metastatic Colorectal Cancer | Peritoneal Carcinomatosis | Colon Adenocarcinoma
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Recruiting

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

T-cell Lymphoma | T-cell Leukemia

China
European Organisation for Research and Treatment...

Recruiting

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)

Stage IB-IIB Cutaneous T-Cell Lymphoma

Spain, United Kingdom, Denmark, Italy, France, Germany, Greece
Dana-Farber Cancer Institute

Recruiting

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Cutaneous T Cell Lymphoma | Peripheral T Cell Lymphoma

United States
Adaptimmune
ICON plc

Recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Melanoma | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Gastric (Stomach) Cancer | Esophagogastric Junction (EGJ) | Non-small Cell Lung (NSCLC)

United States, Canada, Spain, Belgium
Adaptimmune

Recruiting

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Myxoid Liposarcoma | Synovial Sarcoma

United States, United Kingdom, Canada, France, Spain
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
University of Leeds
Takeda; Cancer Research UK; Celgene

Recruiting

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)

Multiple Myeloma

United Kingdom
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin Lymphoma

United States
Immatics US, Inc.

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin Lymphoma

United States
University of Miami

Recruiting

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Adult T-cell Leukemia-Lymphoma | ATLL

United States
Samsung Medical Center

Recruiting

Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

Peripheral T-cell Lymphoma

Korea, Republic of
Altor BioScience
National Cancer Institute (NCI)

Completed

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis

United States
GlaxoSmithKline

Terminated

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Neoplasms

United States, Germany, Netherlands, Canada, Australia, Sweden
GlaxoSmithKline

Terminated

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Neoplasms

Germany, United States, Netherlands, Canada, Australia, Sweden
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Treatment of Acute Lymphoblastic Leukemia in Children

Leukemia | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Adaptimmune

Active, not recruiting

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Neoplasms

United States, Canada, Spain, United Kingdom, Netherlands, France, Italy
M.D. Anderson Cancer Center

Active, not recruiting

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma and other conditions

United States
Instil Bio

Terminated

ITIL-168 in Advanced Melanoma (DELTA-1)

Advanced Cutaneous Melanoma

United States, Canada, United Kingdom
Eureka Therapeutics Inc.

Terminated

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Hepatocellular Carcinoma | Liver Neoplasm | Liver Cancer | Metastatic Liver Cancer

United States
Memorial Sloan Kettering Cancer Center
University of Nebraska

Completed

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

T-cell Lymphomas | Relapsed or Refractory

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid... and other conditions

United States
Instil Bio

Active, not recruiting

ITIL-306 in Advanced Solid Tumors

Renal Cell Carcinoma | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

United States
Immatics US, Inc.
M.D. Anderson Cancer Center

Completed

ACTolog in Patients With Solid Cancers (ACTolog)

Cancer | Solid Tumor

United States
Immatics US, Inc.

Completed

TCR-engineered T Cells in Solid Tumors: IMA202-101 (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Neoplasms

United States, Spain, Netherlands, United Kingdom, Canada
Jason R. Brown
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Active, not recruiting

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Bladder Cancer | Urothelial Carcinoma

United States

Search clinical trials for: eligible for CAR T-cells therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations